[Diffuse interstitial lung disease revealing anti-synthetase syndrome: about two cases].

Une pneumopathie interstitielle diffuse révélant un syndrome des antisynthétases: à propos de 2 cas.

Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet ISSN: 1937-8688 (Electronic) NLM ISO Abbreviation: Pan Afr Med J Subsets: MEDLINE

Original Publication: Kampala, Uganda : African Field Epidemiology Network

Immunosuppressive Agents/*administration & dosage ; Lung Diseases, Interstitial/*etiology ; Myositis/*diagnosis; Adrenal Cortex Hormones/administration & dosage ; Adult ; Aged ; Antibodies, Antinuclear/immunology ; Female ; Humans ; Lung Diseases, Interstitial/drug therapy ; Lung Diseases, Interstitial/physiopathology ; Male ; Myositis/drug therapy ; Myositis/immunology ; Prognosis

Anti-synthetase syndrome (ASS) is an inflammatory myopathy commonly associated with pulmonary involvement, especially parenchymal (diffuse infiltrative pneumonitis). Extrathoracic manifestations associated with pulmonary involvement can give an indication to the diagnosis: myalgias, polyarthralgias, Raynaud's syndrome, erythematous palmar hyperkeratosis with fissures and fever. Given the suggestive clinical and radiological picture, the presence of aminoacyl-transfer RNA (tRNA) synthetase antibodies enables to confirm, in particular, Anti Jo-1 antibody activity. Pulmonary involvement is a major prognostic factor, hence the indication for intensive immunosuppressive therapy based on corticosteroids, immunosuppressive medications or the association among them. A better awareness about this disorder revealed by pulmonary manifestations could enable early and adequate management and to improve patient's prognosis.
Competing Interests: Les auteurs ne déclarent aucun conflit d´intérêts.

Lupus. 2000;9(5):338-42. (PMID: 10878725)
N Engl J Med. 1975 Feb 13;292(7):344-7. (PMID: 1090839)
Ann Rheum Dis. 2001 Feb;60(2):116-23. (PMID: 11156543)
Rheumatology (Oxford). 2002 Jan;41(1):7-13. (PMID: 11792873)
Rev Mal Respir. 2002 Jun;19(3):371-4. (PMID: 12161705)
J Rheumatol. 2005 Jan;32(1):58-64. (PMID: 15630726)
Intern Med. 2005 Apr;44(4):319-25. (PMID: 15897644)
Br J Dermatol. 2007 Jan;156(1):192-4. (PMID: 17199601)
Thorax. 2008 Jan;63(1):53-9. (PMID: 17557770)
Rheumatology (Oxford). 2009 Aug;48(8):968-71. (PMID: 19531628)
Eur Respir J. 2009 Dec;34(6):1219-63. (PMID: 19749199)
Intern Med J. 2011 Sep;41(9):674-9. (PMID: 20059602)
J Rheumatol. 2010 Sep;37(9):1967; author reply 1968. (PMID: 20810525)
Rheumatology (Oxford). 2011 Jun;50(6):1175-6. (PMID: 21454309)
Autoimmun Rev. 2012 Mar;11(5):335-40. (PMID: 21985773)
Autoimmun Rev. 2012 Aug;11(10):739-45. (PMID: 22326685)
Q J Med. 1990 Oct;77(282):1019-38. (PMID: 2267280)
Autoimmun Rev. 2012 Dec;12(2):210-7. (PMID: 22771754)
J Rheumatol. 2012 Sep;39(9):1835-9. (PMID: 22859355)
Am Rev Respir Dis. 1990 Mar;141(3):727-33. (PMID: 2310101)
Arthritis Care Res (Hoboken). 2013 May;65(5):800-8. (PMID: 23203765)
Eur Respir J. 2013 Nov;42(5):1271-82. (PMID: 23397301)
J Clin Apher. 2013 Dec;28(6):422-5. (PMID: 23908096)
Rev Med Interne. 2014 Jul;35(7):453-60. (PMID: 24135060)
Arthritis Res Ther. 2013 Oct 08;15(5):R149. (PMID: 24286268)
Rev Med Suisse. 2015 Apr 8;11(469):808-12. (PMID: 26040161)

Keywords: Antisynthetases syndrome; anti-Jo-1; diffuse infiltrative lung disease; prognosis

0 (Adrenal Cortex Hormones)
0 (Antibodies, Antinuclear)
0 (Immunosuppressive Agents)
0 (Jo-1 antibody)

Antisynthetase syndrome

Date Created: 20190531 Date Completed: 20190607 Latest Revision: 20200225

20250114

PMC6522153

10.11604/pamj.2019.32.40.17903

31143345